Comprehensive Toileting Program
Comprehensive Toileting Programming: Enuresis Treatment to a Randomized Clinical Trial of a Caregiver-Mediated Multidisciplinary Intervention for Encopresis
Emory University
150 participants
Jun 1, 2026
INTERVENTIONAL
Conditions
Summary
The current study aims to monitor fecal continence after autistic youth complete enuresis treatment and for individuals who continue to experience encopresis after acquiring urine continence, evaluate a caregiver-mediated version of a Multidisciplinary Intervention for Encopresis (CM-MIE) delivered via telehealth to determine efficacy in a randomized clinical trial.
Eligibility
Inclusion Criteria5
- Age 5 to 12
- Diagnosis of an intellectual or developmental delay (excluding individuals with ADHD alone)
- Encopresis (more than 1 incontinent BM a week)
- Required for pre-randomization phase only: Enuresis (> 1 incontinent urination per day when on a consistent toileting sit schedule)
- At least one caregiver who speaks and understands English
Exclusion Criteria4
- Unresolved medical condition that would impede toilet training (e.g., interference with sphincter control, short gut syndrome, urinary tract or gastrointestinal infection, unexplained diarrhea, recent intestinal surgery, inflammatory bowel disease)
- Failed intensive toileting treatment in the past 2 yrs with protocols akin to study
- Current serious behavioral or psychiatric disorder that requires another treatment
- Current or planned other intervention (behavioral or medical) for incontinence
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Liquid glycerin suppositories, pediatric (age 2-5 years: 4 ml/applicator) or adult (6-12 years: 7.5ml/applicator) dose used as indicated based on age will be used in the study. Up to two doses will be delivered a day. The purpose of the glycerin suppository is to rapidly evoke a bowel movement, which allows for a predictable bowel movement to occur while the child is seated on the toilet (a continent bowel movement).
The BCBA will provide recommendations on promoting bowel movement continence. The caregiver will be asked to collect data between visits that will be reviewed by the therapist.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07226739